

**Reference Number:** FOI202223/004  
**From:** Private Individual  
**Date:** 01 April 2022  
**Subject:** Number of metastatic non-small cell lung cancer (NSCLC) patients treated with a list of specific drugs

Q1 In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- a. Afatinib
- b. Alectinib
- c. Atezolizumab monotherapy
- d. Atezolizumab in combination
- e. Bevacizumab
- f. Brigatinib
- g. Capmatenib
- h. Ceritinib
- i. Crizotinib
- j. Dacomitinib
- k. Dabrafenib with Trametinib
- l. Docetaxel monotherapy
- m. Durvalumab
- n. Erlotinib
- o. Gefitinib
- p. Gemcitabine
- q. Nintedanib with Docetaxel
- r. Nivolumab
- s. Osimertinib
- t. Paclitaxel
- u. Pembrolizumab monotherapy
- v. Pembrolizumab in combination
- w. Pemetrexed with Carboplatin/Cisplatin
- x. Tepotinib
- y. Vinorelbine with Cisplatin/Carboplatin
- z. Any other SACT
- aa. Palliative care only

A1 [Zero. This is primarily an adult diagnosis and we have not had any patients presenting in the time scale specified.](#)